How to Help Your Patients Save Money on Praluent: A Provider's Guide to Savings Programs

Praluent (alirocumab) is clinically appropriate for a substantial population of cardiovascular patients — but cost and insurance barriers prevent many of them from staying on therapy. A 2022 claims analysis found that only 29% of patients prescribed a PCSK9 inhibitor remained on therapy at 24 months, with cost cited as one of the top two reasons for discontinuation. Proactive enrollment in savings programs is one of the highest-impact interventions a prescribing practice can make. Here's a complete guide.

Understanding the Cost Landscape for Praluent in 2026

Before recommending a savings program, understand your patient's insurance situation:

List price: Approximately $5,850/year following Sanofi's 2018 list price reduction; ~$533–$777/month for two pens without discounts

Commercial insurance: ~50% of commercial plan members have Praluent coverage; prior authorization required across the board; copay varies by plan tier

Medicaid: Covers nearly all enrollees; PA still commonly required

Medicare Part D: Coverage varies by plan; $2,100 out-of-pocket cap applies in 2026 (IRA); manufacturer copay cards prohibited

Program 1: MyPRALUENT Copay Card (Commercially Insured Patients)

The MyPRALUENT Copay Card from Regeneron is the most impactful tool for commercially insured patients. Key details:

Eligible patients may pay as little as $35–$50 per month, covering deductibles, copays, and coinsurance

Maximum assistance: $3,500 per year

No income requirement; requires commercial insurance (not government-funded insurance)

Not valid for Medicare, Medicaid, VA, DOD, or TRICARE

Enrollment: Patients or your office can enroll at praluent.com/starting-and-paying-for-praluent-rx or by calling 1-844-PRALUENT (1-844-772-5836). Enrollment is quick — typically completed online in a few minutes with insurance information. Many specialty pharmacies can also enroll patients at the time of first fill.

Clinical recommendation: Enroll patients in the copay card at the time of prescribing — before the first fill — not after they receive a bill they can't pay.

Program 2: MyPraluent Patient Assistance Program (Uninsured/Underinsured)

For patients without adequate insurance coverage who meet income requirements, the MyPraluent Patient Assistance Program (PAP) provides alirocumab at no cost. Key details:

Eligible patients receive Praluent at no charge for up to 12 months; renewals available

Income documentation required — contact the program for current thresholds

Enrollment: Patient or office calls 1-844-772-5836 or submits electronic enrollment form at praluent.com; your office can submit on the patient's behalf

Workflow tip: If your office handles PA submissions, have the same staff member check PAP eligibility simultaneously. The income and insurance documentation overlaps significantly.

Medicare Patients: Navigating Cost Without Copay Cards

Medicare patients present the most complex cost-management situation: manufacturer copay cards are federally prohibited, and Part D coverage for Praluent varies by plan. Strategies for your Medicare patients:

Confirm Part D coverage before prescribing: Check the patient's specific Part D plan formulary. Coverage and tier placement vary significantly between plans.

Leverage the Part D out-of-pocket cap: The 2026 $2,100 annual out-of-pocket cap means patients who start Praluent in January may reach the cap by April and pay $0 for the rest of the year. For high-medication-burden patients, timing Praluent initiation early in the year maximizes this benefit.

Extra Help / Low-Income Subsidy (LIS): Refer eligible patients (income below ~$22,590/year for individuals in 2025, adjusted annually) to the Social Security Administration to apply. LIS reduces Part D deductibles and copays dramatically.

Consider Leqvio (inclisiran) for Medicare patients: Administered in-office, Leqvio is billed under Part B (80% Medicare coverage after deductible) rather than Part D. This can be significantly cheaper for Medicare patients and bypasses formulary restrictions entirely.

MyPraluent PAP for uninsured Medicare patients: Medicare patients without Part D coverage for Praluent who meet income requirements may still qualify for the PAP. Call 1-844-772-5836 for details.

39,483+ patients found their medications in stock

39K+

Find Praluent In Stock Today →

How to Have the Cost Conversation at Prescribing

Research consistently shows that patients don't volunteer cost concerns to their physicians — they simply don't fill the prescription. Proactively raising cost at the time of prescribing is more effective than reactive intervention after non-adherence.

A simple script for your team: "Before we send this prescription, I want to make sure we've helped you with the cost side. Do you have commercial insurance? We can enroll you in a copay assistance program right now that can bring your out-of-pocket cost down to about $35–$50 a month. If you're uninsured, there's a separate program that may provide the medication at no cost. Which situation applies to you?"

Supporting Access After Prescribing

Even after PA approval and savings program enrollment, some patients struggle to find Praluent at their preferred pharmacy. medfinder for providers calls pharmacies near the patient to check which ones have Praluent in stock and can fill the prescription — reducing the follow-up burden on your office staff and improving time-to-therapy for patients.

For a comprehensive review of the Praluent access landscape, prior authorization strategies, and formulary navigation, see our Praluent provider access briefing.